mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops

Tumor Biology

Volumn 33, Issue 3, 2012, Pages 885-890

  Galoian, Karina ^a   Temple, H T ^a   Galoyan, Armen ^b  

^a UNIVERSITY OF MIAMI HEALTH SYSTEM   (United States)

^b H Buniatian Institute of Biochemistry National Academy of Sciences of Armenia   (Armenia)

Author keywords

Chondrosarcoma; ECM cell adhesion; mTORC1; Multidrug resistance

Indexed keywords

BETA CATENIN; FOCAL ADHESION KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOPROTEIN; HISTONE DEACETYLASE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PRP1 PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG; HISTONE ACETYLTRANSFERASE; MTORC1 COMPLEX, HUMAN; PEPTIDE; PROTEIN; PRP 1 PEPTIDE; PRP-1 PEPTIDE;

ARTICLE; CANCER RESISTANCE; CELL ADHESION; CHONDROSARCOMA; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; UPREGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL ADHESION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84863594685     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0315-x     Document Type: Article

References (34)

1. Carracedo A, Baselga J, Pandolfi PP. Deconstructing feedbacksignaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle. 2008;7(24):3805-9.
2. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3Kdependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065-74.
3. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500-8.
4. Grant S. Cotargeting survival signaling pathways in cancer. J Clin Invest. 2008;118(9):3003-6.
5. Galoyan AA. Neurochemistry of brain neuroendocrine immune system: signal molecules. Neurochem Res. 2000;25(9/10):1343. 55.
6. Galoian K, Scully S, Galoyan A. Myc-oncogene inactivating effect by proline-rich polypeptide 1 (PRP-1) in chondrosarcoma JJ012 cells. Neurochem Res. 2009;34(2):379-85.
7. Galoian K, Scully S, McNamara G, Flynn P, Galoyan A. Antitumorigenic effect of brain proline-rich polypeptide 1 in human chondrosarcoma. Neurochem Res Neurochem Res. 2009;34(12):2117-21.
8. Galoian K. Temple T. H, Galoyan A. Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by mTOR and cMyc inhibition in high-grade chondrosarcoma. Neurochem Res. 2011;36:812-8.
9. Galoian KA, Temple TH, Galoyan A. Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER-) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors. Tumour Biol. 2011;32(4):745-51.
10. Thomas Parsons J, Slack-Davis J, Tilghman R, Gregory Roberts W. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res. 2008;627:1-14.
11. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2002;5:234-48.
12. Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev. 2011. doi:10.1002/med.20239.
13. Thornton TM, Pedraza-Alva G, Deng B, Wood CD, Aronshtam A, Clements JL, Sabio G, Davis RJ, Matthews DE, Doble B, Rincon M. Phosphorylation by p38 MAPK as an alternative pathway for GSK3β inactivation. Science. 2008;320(5876):667-70.
14. Zoubeidi A, Zardan A, Wiedmann RM, Locke J, Beraldi E, Fazli L, Gleave ME. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res. 2010;70:2307.
15. Shimamura A, Ballif BA, Richards SA, Blenis J. RSK1 mediates a MEK. MAP kinase cell survival signal. Curr Biol. 2000;10(3):127-35. 1.
16. Sakamoto KM, Frank DA. CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res. 2009;15:2583.
17. Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M. Cross-talk between AKT, p53, and MDM2: possible implications for the regulation of apoptosis. Oncogene. 2002;21(8):1299-303.
18. Alao JP, Stavropoulou AV, Lam EW-F, Charles Coombes R. Role of glycogen synthase kinase 3 beta (GSK3β) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells. Mol Cancer. 2006;5:40.
19. Walkinshaw DR, Yang XJ. Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol. 2008;15(5):237-43.
20. Ribeiro MSJ, Hansson ML, Lindberg MJ, Popko-Ścibor AE, Wallberg AE. GSK3β is a negative regulator of the transcriptional coactivator MAML1. Nucl Acids Res. 2009;37(20):6691-700.
21. Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X, Mankin H, Duan Z. Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines. Anticancer Res. 2011;31(4):1115-23.
22. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59:111-37.
23. Yu C, Friday BB, Lai JP, McCollum A, Atadja P, Roberts LR, Adjei AA. Abrogation of MAPK and AKT signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res. 2007;13(4):1140-8.
24. Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Muller-Brusselbach S. O G Ottmann, J Duyster, A Hochhaus, A Neubauer. Chronic myeloid leukemia, BCR QBL studies QND. Myeloproliferative disorders. Compensatory PI3-kinase/AKT/mTor activation regulates imatinib resistance development. Leukemia. 2007;19:1774-82.
25. Schwab J, Antonescu C, Boland P, Healey J, Rosenberg A, Nielsen P, Iafrate J, Delaney T, Yoon S, Choy E, Harmon D, Raskin K, Yang C, Mankin H, Springfield D, Hornicek F, Duan Z. Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma. Anticancer Res. 2009;29(6):1867-71.
26. Lopez-Fauqued M, Gil R, Grueso J, Hernandez-Losa J, Pujol A, Moline T, Recio JA. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. Int J Cancer. 2010;126(7):1549-61.
27. Woodward JKL, Rennie IG, Elshaw SR, Burnand JL, Sisley K. Invasive and noninvasive uveal melanomas have different adhesive properties. Eye. 2005;19:342-8.
28. Bergin E, Levine JS, Koh JS, Lieberthal W. Mouse proximal tubular cell.cell adhesion inhibits apoptosis by a cadherindependent mechanism. A/J Physiol Renal Physiol. 2000;278:F758.68.
29. Turner S, Sherratt JA. Intercellular adhesion and cancer invasion: a discrete simulation using the extended potts model. J Theor Biol. 2002;216:85-100.
30. Lin TH, Aplin AE, Shen Y, Chen Q, Schaller M, Romer L, Aukhil I, Juliano RL. Integrin-mediated Activation of MAP kinase is independent of FAK: evidence for dual integrin signaling pathways in fibroblasts. J Cell Biol. 1997;136(6):1385-95.
31. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93(5):1658-67.
32. Bozzo C, Bellomo G, Silengo L, Tarone G, Altruda F. Soluble integrin ligands and growth factors independently rescue neuroblastoma cells from apoptosis under nonadherent conditions. Exp Cell Res. 1997;237(2):326-37.
33. Cordes N, van Beuningen D. Cell adhesion to the extracellular matrix protein fibronectin modulates radiation-dependent G2 phase arrest involving integrin-linked kinase (ILK) and glycogen synthase kinase 3 beta (GSK3β) in vitro. May 6, 2003;88(9):1470-1479.
34. Huanwen W, Zhiyong L, Xiaohua S, Xinyu R, Kai W, Tonghua L. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol Cancer. 2009;8:125. 21.